Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IKTNASDAQ:IZTCNYSE:PLXNASDAQ:TCRR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.89+2.2%$1.94$1.12▼$4.20$140.51M0.92276,837 shs81,965 shsIZTCInvizyne Technologies$9.91-2.8%$12.46$8.50▼$23.00$103.16MN/A37,647 shs1,256 shsPLXProtalix BioTherapeutics$1.55+3.0%$1.79$0.82▼$3.10$122.99M-0.23579,876 shs409,479 shsTCRRTCR2 Therapeutics$1.48$1.65$0.82▼$3.88$58.11M1.95494,777 shsN/A7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics0.00%+16.67%-3.57%+2.72%+64.28%IZTCInvizyne Technologies+1.64%-4.62%-26.59%-0.40%+990,999,900.00%PLXProtalix BioTherapeutics0.00%+0.32%+1.64%-35.36%+45.75%TCRRTCR2 Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIKTInhibikase Therapeutics1.3607 of 5 stars3.31.00.00.01.80.00.6IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/APLXProtalix BioTherapeutics2.9048 of 5 stars3.53.00.00.01.90.01.9TCRRTCR2 TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics 2.50Moderate Buy$6.50243.92% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/APLXProtalix BioTherapeutics 3.00Buy$15.00870.87% UpsideTCRRTCR2 Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/APLXProtalix BioTherapeutics$59.76M2.06$0.09 per share17.80$0.47 per share3.29TCRRTCR2 TherapeuticsN/AN/AN/AN/A$2.58 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/AIZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/APLXProtalix BioTherapeutics$8.31M$0.04N/A4.98N/A-21.03%-30.89%-11.74%N/ATCRRTCR2 Therapeutics-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/ALatest TCRR, IKT, PLX, and IZTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A0.850.85IZTCInvizyne TechnologiesN/AN/AN/APLXProtalix BioTherapeuticsN/A1.981.27TCRRTCR2 TherapeuticsN/A2.962.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%IZTCInvizyne TechnologiesN/APLXProtalix BioTherapeutics16.53%TCRRTCR2 Therapeutics64.76%Insider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics7.30%IZTCInvizyne TechnologiesN/APLXProtalix BioTherapeutics6.50%TCRRTCR2 Therapeutics25.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableIZTCInvizyne Technologies296.25 millionN/AN/APLXProtalix BioTherapeutics20079.61 million69.00 millionOptionableTCRRTCR2 Therapeutics13739.26 million29.44 millionNot OptionableTCRR, IKT, PLX, and IZTC HeadlinesRecent News About These CompaniesTCR2 Therapeutics gets grant for recombinant nucleic acid encoding TCR fusion protein for cancer treatmentApril 17, 2024 | pharmaceutical-technology.comPPoseida Therapeutics Inc Ordinary Shares PSTXFebruary 25, 2024 | morningstar.comMDICE Therapeutics Inc.June 20, 2023 | wsj.comAdaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy CompanyJune 1, 2023 | finance.yahoo.comTCR2 Therapeutics Insider Trades Send a SignalMay 16, 2023 | benzinga.comRecap: TCR2 Therapeutics Q1 EarningsMay 12, 2023 | msn.com10-Q: TCR2 THERAPEUTICS INC.May 11, 2023 | marketwatch.comTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 11, 2023 | finance.yahoo.comCompanies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite RiskyApril 15, 2023 | finance.yahoo.comMizuho Downgrades Tcr2 Therapeutics (TCRR)March 25, 2023 | msn.comTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho SecuritiesMarch 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)March 23, 2023 | markets.businessinsider.comTCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateMarch 23, 2023 | finanznachrichten.deTCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateMarch 23, 2023 | finance.yahoo.comWhat To Know About Jefferies's Downgrade of TCR2 TherapeuticsMarch 9, 2023 | msn.com4 Analysts Have This to Say About TCR2 TherapeuticsMarch 9, 2023 | markets.businessinsider.comTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. WainwrightMarch 8, 2023 | markets.businessinsider.comShareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with AdaptimmuneMarch 6, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. BuyoutMarch 6, 2023 | benzinga.comWhy Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?March 6, 2023 | investorplace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTCRR, IKT, PLX, and IZTC Company DescriptionsInhibikase Therapeutics NYSE:IKT$1.89 +0.04 (+2.16%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Invizyne Technologies NASDAQ:IZTC$9.91 -0.29 (-2.84%) As of 07/3/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Protalix BioTherapeutics NYSE:PLX$1.54 +0.05 (+3.00%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$1.54 0.00 (0.00%) As of 07/3/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.TCR2 Therapeutics NASDAQ:TCRRTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.